Just reported
From Merck's results release of 29 Ekim 2026; its quarterly report has since been filed.
Actual
$18,09B
+%4,7 y/y
+%8,9 q/q
Guided
—
No guide given
Actual
$2,04
-%12 y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Gelir payları FY2025 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
Keytruda and Keytruda Qlex
Cancer medicines. Keytruda is given into a vein; Keytruda Qlex is a form given as an injection under the skin.
Gardasil and Gardasil 9
Vaccines that help prevent certain cancers and other diseases caused by some types of human papillomavirus.
Januvia and Janumet
Prescription medicines used to help lower blood sugar in adults with type 2 diabetes.
Winrevair
A medicine for adults with pulmonary arterial hypertension, a disease that raises blood pressure in the arteries from the heart to the lungs.
Lipfendra
An oral medicine used with diet and exercise to lower low-density lipoprotein cholesterol in adults with high cholesterol.
Bravecto
A range of medicines that protect dogs and cats against fleas and ticks, including oral, topical and injectable forms.
Merck discovers, develops, manufactures and sells prescription medicines and vaccines for people, including cancer treatments such as Keytruda and vaccines such as Gardasil. Its Animal Health business sells medicines, vaccines and animal identification and monitoring products to veterinarians, farmers and other animal-care businesses.
Merck & Co., Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
The themes Merck is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$147,76+%0,613 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 4 Kasım 2026 tarihinde sunulan 10-Q raporundan
Merck makes prescription medicines and vaccines for people, and medicines, vaccines and monitoring products for animals.
Grade A
Fiyatın altındaki şerit, her tarihteki notu gösterir; yalnızca o tarihe kadar yayımlanmış belgelerden hesaplanır.
Merck & Co., Inc. şirketinin not geçmişinin 41 çeyreğinden 2 tanesi gösteriliyor. Diğer 39 çeyrek Kasım 2016 tarihine kadar uzanıyor.